Health Canada Begins Consultations on Mandatory Reporting by Health Care Institutions

Health Canada Begins Consultations on Mandatory Reporting by Health Care Institutions

Published on July 17, 2017

Author: Mark Vanderveken and Alanna Tevel

Health Canada has commenced consultations on proposed changes to the Food and Drug Regulations and Medical Devices Regulations that would require mandatory reporting of serious adverse drug reactions and medical device incidents by health care institutions. The changes are pursuant to amendments to the Food and Drugs Act contained in the Protecting Canadians from Unsafe Drugs Act, which was enacted in November 2014. Health Canada published a Notice of Intent to amend the regulations in June 2016.

The proposed changes are intended to enhance post-market surveillance of drugs and medical devices to improve identification of emerging patient safety issues.

Health Canada is seeking input on five elements of the proposed changes to the regulations:

chart

Comments on non-regulatory approaches to improve reporting of serious adverse drug reactions and medical device incidents, including outreach, education, and feedback for reporting institutions, are also being solicited.

More information on the proposed changes can be found on Health Canada’s consultation webpage and in the accompanying Consultation Paper. The online consultation period ends on August 11, 2017. Health Canada expects that the proposed changes will be implemented, at the earliest, in 2019.

Related Articles

Pragmatic Clinical Trials: Testing Treatments in the Real-World

Pragmatic Clinical Trials: Testing Treatments in the Real-World

What is a Pragmatic Clinical Trial? Clinical trials can be designed to be either pragmatic or explanatory. Explanatory trials are designed to find out whether a treatment...

The FDA Announces Proposed Rule: Nonprescription Drug Product with an Additional Condition for Nonprescription Use – June 28, 2022

The FDA Announces Proposed Rule: Nonprescription Drug Product with an Additional Condition for Nonprescription Use – June 28, 2022

The FDA is announcing the availability of the proposed rule Nonprescription Drug Product with an Additional Condition for Nonprescription Use (Docket No. FDA-2021-N-0862)....